---
title: "Understanding the Market | MICROPORT rises over 5%, Endovastec's annual net profit attributable to the parent company increases by 12.17%, and the company's research products are progressing steadily"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277873418.md"
description: "MicroPort's stock price rose by more than 5%, with an increase of 5.19% as of the time of publication, trading at HKD 1.42, with a transaction volume of HKD 19.4691 million. The company announced the 2025 performance preliminary report for Endovastec, with total operating revenue of approximately RMB 1.351 billion, a year-on-year increase of 11.96%; net profit attributable to the parent company of approximately RMB 563 million, a year-on-year increase of 12.17%. Overseas sales revenue exceeded RMB 250 million, with a year-on-year increase of over 55%. The company's research and development products are progressing steadily, including multiple projects such as Aegis II and Hector"
datetime: "2026-03-05T06:22:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277873418.md)
  - [en](https://longbridge.com/en/news/277873418.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277873418.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277873418.md) | [繁體中文](https://longbridge.com/zh-HK/news/277873418.md)


# Understanding the Market | MICROPORT rises over 5%, Endovastec's annual net profit attributable to the parent company increases by 12.17%, and the company's research products are progressing steadily

According to Zhitong Finance APP, MICROPORT (00853) rose over 5%, as of the time of writing, up 5.19% to HKD 1.42, with a transaction volume of HKD 19.4691 million.

In terms of news, recently, MICROPORT announced the preliminary annual performance report for Endovastec in 2025, with total operating revenue of approximately RMB 1.351 billion, a year-on-year increase of 11.96%; net profit attributable to the parent company was approximately RMB 563 million, a year-on-year increase of 12.17%; basic earnings per share were RMB 4.65. During the reporting period, the company's overseas sales revenue exceeded RMB 250 million, a year-on-year increase of over 55%, accounting for more than 18% of the company's total revenue. The company continues to promote cooperation with leading regional industry clients globally and advance the market access and promotion of aortic and peripheral interventional products in countries across Europe, Latin America, and Asia-Pacific.

The company's research and development products are progressing steadily, with a rich pipeline. The Aegis II abdominal aortic stent graft system has completed the submission of registration materials; the Hector thoracic main multi-branch stent graft system has entered the pre-market multi-center clinical stage in China and has entered the national innovation "green channel" during the reporting period, achieving commercialization through EU customization. Additionally, the application for the Breakthrough Device Designation for this product has been submitted to the FDA; the thoracic and abdominal aortic stent graft system (customized) has obtained domestic filing certification; the iliac artery branch stent graft system is about to enter the clinical trial initiation stage

### Related Stocks

- [MP CARDIOFLOW-B (02160.HK)](https://longbridge.com/en/quote/02160.HK.md)
- [MICROPORT NEURO (02172.HK)](https://longbridge.com/en/quote/02172.HK.md)
- [MICROPORT (00853.HK)](https://longbridge.com/en/quote/00853.HK.md)
- [Endovastec (688016.CN)](https://longbridge.com/en/quote/688016.CN.md)
- [MircroPort Medbot-B (02252.HK)](https://longbridge.com/en/quote/02252.HK.md)

## Related News & Research

- [11:33 ETFitness, Health and Wellness Experts Team Up to 'Get Fit for No Kid Hungry' with New On-Demand Initiative](https://longbridge.com/en/news/281213207.md)
- [MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars](https://longbridge.com/en/news/278748555.md)
- [MicroPort CardioFlow Merges with MicroPort CRM](https://longbridge.com/en/news/275426231.md)
- [MicroPort MedBot Forecasts Revenue Surge and Sharply Narrowed Loss on Toumai Robot Boom](https://longbridge.com/en/news/273253690.md)